BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) P/B ratio
As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a P/B ratio of 9.9×. Over the past ten years it has ranged from 0.0× (December 2025) to 13.0× (August 2026); the current reading is higher than 84% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.7× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 9.4× | (9.63%) |
| Jun 2026 | 10.4× | 44.63% |
| Mar 2026 | 7.2× | 165.00% |
| Dec 2025 | 2.7× | — |
| 4 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| VCYT Veracyte, Inc. compare | 1.4× |
| GRAL GRAIL, Inc. compare | 2.4× |
| NEO NeoGenomics, Inc. compare | 2.7× |
| QGEN QIAGEN N.V. compare | 3.1× |
| RDNT RadNet, Inc. compare | 4.4× |
| SHC Sotera Health Company compare | 6.2× |
| CDNA CareDx, Inc. compare | 8.6× |
| BLLN BillionToOne, Inc. | 9.9× |
| ADPT Adaptive Biotechnologies Corporation compare | 23.5× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement